Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of⦠read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
$1.55
Price+2.39%
$0.04
$111.521m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$26.865m
-
1y CAGR-
3y CAGR-
5y CAGR-$162.783m
-
1y CAGR-
3y CAGR-
5y CAGR-$2.27
-
1y CAGR-
3y CAGR-
5y CAGR$274.495m
$351.707m
Assets$77.212m
Liabilities$37.690m
Debt10.7%
-0.2x
Debt to EBITDA-$151.091m
-
1y CAGR-
3y CAGR-
5y CAGR